BD 1047 (hydrobromide) – 10 mg

Brand:
Cayman
CAS:
138356-21-5
Storage:
-20
UN-No:
Non-Hazardous - /

BD 1047 is a selective antagonist of sigma-1 (σ1) receptors (Ki = 0.9 nM in a radioligand binding assay).{39221} It is selective for σ1 receptors with binding affinity values greater than 10,000 nM for human recombinant dopamine, opioid, PCP, and serotonin receptors in vitro. In vivo, pretreatment with BD 1047 protects against convulsions and lethality induced by cocaine (Item Nos. 16186 | ISO60176) and reduces cocaine-induced locomotor activity. It reduces dystonias induced by the σ receptor agonists haloperidol (Item No. 12014) and di-o-tolylguanidine (DTG) in rats in a dose-dependent manner.{39220} In vivo administration of BD 1047 also attenuates mechanical allodynia and microglial activation in a rat model of bone cancer pain.{39222}  

 

Available on backorder

SKU: 22928 - 10 mg Category:

Description

A selective antagonist of σ1 receptors (Ki = 0.9 nM in a radioligand binding assay); selective for σ1 receptors with binding affinity values greater than 10,000 nM for human recombinant dopamine, opioid, PCP, and serotonin receptors in vitro; protects against convulsions and lethality induced by cocaine and reduces cocaine-induced locomotor activity; reduces haloperidol- and DTG-induced dystonias in vivo; attenuates mechanical allodynia and microglial activation in a rat model of bone cancer pain,


Formal name: N1-[2-(3,4-dichlorophenyl)ethyl]-N1,N2,N2-trimethyl-1,2-ethanediamine, dihydrobromide

Synonyms: 

Molecular weight: 437

CAS: 138356-21-5

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Neuroscience|Behavioral Neuroscience|Addiction Research||Research Area|Neuroscience|Pain Research||Research Area|Neuroscience|Seizure Disorders